MOLN · Molecular Partners AG
Market Cap
$164.71M
Shares
38.31M
Volume · Oct 5
760
Avg daily vol (3M)
3309
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.91
Open$4.08
Day$3.91–4.08
52W close$3.54–5.13
Avg vol 30d2K
Short int218 · 0.0% float · 1.0d
Short vol38%
Last earningsAug 25, 2026
DataJun 2021–Sep 2026
Up next
Next earnings call
May 19, 2027
Est · unconfirmed
· in 32 wks
call held Jan 10, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$64.52M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-35.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year · more shares
Price change (1Y)
+5.4%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
−5%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
23%
mid-range
Momentum
relative strength
1-month return
−11%
trailing
6-month return
−10%
trailing
YTD return
−10%
this year
Relative strength
−22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+25% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -0.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
5 holders — mid 3-yr range
Squeeze score
24
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
59%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
−5%
Bearish
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
23%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+25% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -0.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
5 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $4 · 23%
Range high $5
vs 200-day avg -7%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MOLN
this stock
Molecular Partners AG
|
$164.71M | -10.3% | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MOLN | -2.0% | -11.1% | -9.9% | -13.1% | -10.3% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -1.3% | -11.3% | -22.1% | -12.5% | -22.1% |